
Indian Journal of
AEROSPACE
MEDICINE
WINTER 2004 VOLUME 48 NUMBER 2
INDIAN SOCIETY OF
AEROSPACE MEDICINE

Original Article

Rotational field quantum magnetic resonance (RFQMR) in treatment of osteoarthritis of the knee joint

Wg Cdr VG Vasishta*, Dr RV Kumar+, Surg Cdr LJ Pinto#

ABSTRACT

Rotational Field Quantum Magnetic Resonance (RFQMR) is a technology that is made to deliver highly complex quantum electromagnetic beams in the sub-radio and near-radio frequency spectrum. The beams can be precisely controlled and focused onto tissues therein generating streaming voltage potentials. In osteoarthritis, this flow in the joint causes forced movement of hydrogen protons in the extra cellular matrix (ECM) due to the alteration in QMR spin in the hydrogen atoms and stimulates the chondrocytes. Thirty-five patients of osteoarthritis were treated with RFQMR focused on both knees for one hour every day for 21 days. They were evaluated before, immediately post treatment and one month after treatment with the Knee Society Scoring System and dynamometry. There was highly significant improvement in Pain Score, Total Knee Score, Total Functional Score, Range of Movement and force of extension, immediately after the treatment vis-a-vis pre treatment values and this improvement persisted when evaluation was repeated after one month. RFQMR is an effective method of treatment of osteoarthritis of the knee joint.

IJASM 2004; 48(2) : 1 - 7

KEY WORDS: Rotational field quantum magnetic resonance, Osteoarthritis

Rotational Field Quantum Magnetic Resonance (RFQMR) beams are delivered by a new computer controlled device called 'Cytotron' (Fig 1) that generates precise high intensity Quantum Magnetic Resonance beams from 96 specially designed Mn-Pb-Cu guns (Fig 2) that are focused on a target tissue. It is believed to alter the cell membrane potential in a highly controlled fashion [1,2]. Osteoarthritis is a degenerative disease caused by the loss of cartilage from load bearing joints, especially the knees, causing impairment of movement and often severe pain. Many kinds of therapies, including newer drugs have been tried with very little or no success, leaving patients with the only surgical option of joint replacement. This is often beyond the financial reach of patients especially in developing countries [3].

RFQMR Hypothesis in Tissue Regeneration

The study of the interactions between electromagnetic fields and living matter has become a fertile field for research in this century, even though these phenomena have been observed by various civilisations since ancient times. Considerable experimental evidence today points to the possibility of modulating biological functions and structures in a controlled way by inducing electromagnetic (EM) resonance and vice versa, the possibility of detecting and measuring endogenous EM resonance in living organisms and their components as an indicator of biological functions.

* *Professor and Head, Department of Radiology, IAM, IAF, Vimanapura PO Bangalore-560017*

\+ *Chief Scientific Officer, Center for Advanced Research and Development, Bangalore*

\# *Professor Aerospace Medicine and Head, Department of Human Engineering IAM, IAF, Bangalore -560017*

Fig 1: CYTOTRON RFQMR Machine

Fig 2: Typical QM 60 RFQMR Gun.

There are three types of EM effects on living matter: ionising, thermal and non-thermal effects [4]. Thermal effects induce an increase of entropic disorder in the target, until at certain frequencies and power levels, the effects of ionisation develop. The non-thermal effects are not the result of the transfer of erratic movement by means of an increase of kinetic energy, but rather, in line with the theories of the coherence of condensed matter, they can transmit information that would produce order in the biostructures involved. It is like the tissue response to radio frequency pulse during magnetic resonance imaging. The information content of the quantum EM beams would depend specifically on the waveform, the string of waves, and the time sequence of their modulation. In fact, specific variations in the configuration and temporal exposure patterns of extremely weak EM fields can produce highly specific biological responses, similar to pharmaceutical products [5]. These non-thermal effects are attracting considerable scientific interest mainly because a quantum EM beam is easily modulated and thus is an excellent means for the transmission of information. Studies carried out by various authors suggest the possibility of utilising non-thermal effects even in causing electroporation of the cell membrane [6,7,8,9] to therapeutic advantage.

RFQMR is a technology that is made to deliver highly complex quantum electromagnetic beam pattern in the sub-radio and near-radio frequency spectrum, with precise external command and control.

Based on these studies, it is reasonable to consider patterns in living matter that take into account the EM components of biological structures. Every cell, for instance, is made up of biological and chemical components that can be described in progressively simpler terms down to the elementary molecular constituents of the cells. The cell itself and its internal and external interactions can also be considered in terms of electric and electromagnetic interactions and relationships [10,11,12,13]. Numerous experimental works have shown the possibility of modifying and controlling the selective permeability of the cell membrane by transmitting specialised quantum EM beams. This leads to the possibility of verifying the specific reactions of healthy cells vis-a-vis the reactions of pathological cells and subsequently selecting target cells for therapeutic intervention. Pathological cells are different from healthy cells due to a different tissue composition.

Various authors have reported the modulation of some cell functions, from ionic membrane pumps to many cytoplasmic enzyme reactions, including those connected with cell replication. From these studies it has been seen that the desired effects can be obtained from non-ionising non-thermal RFQMR beams.

Like other tissues, bone and cartilage are constantly being built up and broken down by a variety of metabolic and physical influences. The

major stimulus for bone and cartilage formation is a piezoelectric signal generated when these structures are subjected to tension or compression [14,15]. This explains why bone atrophies in the absence of any significant pressure, like weightlessness during space travel or immobilization in a cast.

The transmission of this signal is also impaired following joint injury due to trauma or diseases such as osteoarthritis [16]. RFQMR is designed to characterise and reproduce the piezoelectric signal by altering membrane potential of chondrocytes. This initiates regenerative activities by the induction of a spin in the hydrogen atoms and creates a streaming potential in the extracellular matrix (ECM) similar to that, when bone or cartilage are placed under a load.

In other words, when one takes a step, putting weight on the joint, it compresses the cartilage and thereby displaces the fluid, carrying with it mobile ions, sodium ions and leaves behind the negatively charged proteoglycan carboxyl and sulfate ions. This generates an electric potential due to deneutralisation of negative charges. This is called a Streaming Potential [17].

RFQMR can recreate this Streaming Potential and its restorative rewards in joints impaired due to disease or trauma even though they are at rest. The mechanism of producing this Streaming Potential during resting, natural regeneration while loading and RFQMR induced regeneration of cartilage can be simply put as follows:

(a) **At rest.** No change in equilibrium between hydrogen protons and negative charge carriers in the extracellular cartilage matrix. Therefore no Streaming Potential, no regeneration at rest.

(b) **Natural regeneration.** A Streaming Potential is created in the ECM during load bearing caused by the efflux of fixed negative charged fluid forced out of cartilage tissue with active influx of hydrogen protons.

(c) **RFQMR induced regeneration.** Generation of streaming voltage potential flow in the joint is caused by forced movement of hydrogen protons in the ECM due to the alteration in QMR spin in the hydrogen atoms, causing stimulation of chondrocytes in the ECM.

The present study embodies the results of a new successful and relatively inexpensive treatment of osteoarthritis by the application of Rotational Field Quantum Magnetic Resonance (RFQMR) simultaneously to both knees.

Material and Methods

Thirty-five random subjects, with radiologically severe osteoarthritis were recruited for the study. The condition of their knee joints was first assessed by X-Ray and ultrasound examination at the Department of Radiology, Institute of Aerospace Medicine (IAM), Indian Air Force (IAF), Bangalore. Physical parameters such as height, weight, thigh girth, length of tibia, alignment and stability, goniometric and dynamometric measurements were carried out at the Department of Human Engineering, IAM, IAF. Goniometric measurements included evaluation of flexion, range of movement, extension lag, lateral and antero-posterior stability. Dynamometric evaluation involved assessment of extension power of each leg measured with weights in the multigym. Subjective factors such as pain and other disabilities were assessed by implementing the widely accepted Knee Society clinical rating system [18]. These measurements were made both before and after treatment. The data was fed into the computer at the Center for Advanced Research and Development (CARD) and the scores were recorded as per the International Knee Society scoring system.

Informed consent as approved by the Institute's Ethics Committee was obtained from all the patients. The knees of the subjects were exposed everyday for one hour for 21 successive days to the RFQMR beams delivered by the Cytotron, developed by CARD for the purpose. After the completion of 21 exposures, the patients

were re-assessed radiologically and by other human engineering parameters.These were based on inputs for the Knee Society scoring system. The results were fed as inputs to the computer software to assess the knee society scores. Ultrasound of the knee was done to plan the dosage and map the region of interest. The assessment was repeated 30 days after completion of the treatment.

Statistical Analysis

For the purpose of statistical analysis, each knee was taken as one case. Normality of the distribution of data was examined using Shapiro Wilks 'w' statistic. Physical attributes of male and female subjects followed normal distribution and therefore were compared using an unpaired 't' Test. Treatment effect measured as Pain Score [P], Range of Movement [ROM], Total Knee Score [TKS] and Total Functional Score [TFS], exhibited significant departure from normality and therefore were compared using Wilcoxon Matched Pairs Test. Comparison of these variables between the male and female groups was done with Mann Whitney test. Spearman's rank order correlation was attempted between physical attributes and treatment effect. All values are given as mean $\pm$ SD.

Results

The Knee Society score consisting of P, TKS, TFS and ROM were analysed. According to the Knee Society scoring, P has a maximum scale of 50 for 'no pain', the TKS has a maximum scale of 100 being 'the best', TFS also has a maximum scale of 100 and ROM has a maximum of 25 indicating 'normal or maximum' range of movement.

Pain

The values indicated against 'Pain' are inversely proportional to the degree of pain. Zero representing excruciating pain-restricting mobility. These patients were almost confined to the wheel chair and they could move their legs only while sitting in the chair. Every patient showed improvement after the course of treatment. In all the cases there was a significant abatement of pain after the third or fourth day of treatment and the pain progressively reduced during the course of exposure to RFQMR (Fig 3).

The histograms shown below depict centre points as median values, margins of boxes represent 25% and 75% percentiles and whiskers as minimum and maximum values in all graphical representations.



Fig 3 : Pain Score

Range of Movement

The range of movement increased progressively in every patient, the graph below shows the change in ROM during the course of treatment (Fig 4).



Fig 4 : Range of Movement

Total Knee Score and Total Functional Score

TKS and TFS improved spectacularly in all the patients, who were able to walk comfortably for considerable distances at the end of the treatement (Fig 5 and 6).



Fig 5: Total Knee Score



Fig 6: Total Functional Score

While in younger patients the relief was evident within a couple of days of treatment, the rate of relief was slower in older patients who experienced a significant degree of relief on the 6th or 7th day of treatment. However at the end of the treatment the older patients had better TKS and P.

Further, patients with radiologically severe osteoarthritis improved symptomatically better than those who had mild to moderate osteoarthritis. This probably is due to the fact that a small change in these subjects would produce a great amount of symptomatic relief. Evidently, age of the patient plays an important role in the rate and degree of relief. TKS and P showed significant inprovement in older patients. Patients with mild to moderate osteoarthritis reported fairly fast improvement in their pain and walking abilities midway during the treatement.

Dynamometry

Dynamometry was done on all the patients to assess the load bearing capacity of the knee joint. After 21 days of treatment with RFQMR, most patients could push 2 to 3 times the weight they could push before the treatment, indicating that the power of the leg from the thigh to the ankle as revealed by the extension pressure of the whole leg had improved considerably. In other words, they had greater control over their knee joint.

The histogram indicating the dynamometry outcomes before and after the treatment is indicated below (Fig 7).



Fig 7: Dynamometry

The two gender groups were comparable in age, male subjects were taller and heavier as in Table 1 (p=0.756, 0.000 and 0.011 for age, height and weight, respectively; unpaired student's 't' Test).

Table - 1: Physical attributes of the subjects (N=35)

	Age (yrs)	Ht (cms)	Wt (kgs)	n
F	58±7	154±7	73±13	25
M	59±6	167±4	86±12	10
Pooled	59±7	157±9	77±14	35

Correlation of Patient Attributes with Treatment Benefit

Effect of treatment had no correlation with height or weight. However, age correlated significantly with improvement (difference between pre and post values) in terms of P and TKS (Table 2).

Table - 2: Effect of treatment (N=70*)

	Pre Treatment	Post Treatment	p**
P	14 ± 14	35 ± 8	0.000
ROM	15 ± 3	16 ± 2	0.001
TKS	36 ± 17	60 ± 9	0.000
TFS	42 ± 20	68 ± 21	0.000

* Each knee was taken as a separate case.

** Using Wilcoxon Matched Pairs Test

P, TKS, ROM, TFS and dynamometry did not show any correlation with height, weight or age (Table 3). The statistical treatment here was using Spearman's Rank Order Correlation, considered appropriate for the data type. All the other correlations were non-significant.

Table - 3: Correlation of subjects with treatment benefit

	Pain	ROM	TKS	TFS	DYN#
Age	0.279*	-0.077	0.238**	-0.053	0.064
Ht (cm)	-0.137	0.118	-0.161	-0.015	0.068
Wt (kg)	-0.011	-0.016	-0.025	-0.076	0.175

* p=0.019; ** p=0.047, #Dynamometry

Gender Difference in the Responsiveness to Treatment

There was no gender difference in response to treatment as evident from results of Mann Whitney U Test (p=0.346, 0.158, 0.269 & 0.351 for P, ROM, TKS and TFS, respectively). Details of these data are hence not presented.

Discussion

Hyaline cartilage, which forms a cap on the long bones and the inner surface of the patella in the knee joint, is constantly produced from the chondroblastic layer. This process is continuously activated by the constant use of the joint. Disuse atrophy, which is a well known biological phenomenon, applies specially to the knee joint since it is the most important load bearing joint in the human body. The disuse of the joint shows its effect in the form of degeneration of cartilage in the articular surfaces of the bones in the knee joint. Overuse, constant impact and injuries lead to early onset of degenerative change. The rate and extent of degeneration depend on the degree of disuse and the process of aging in the individual. Consequently, older persons exhibit a rapid progress of osteoarthritis because the regenerative capacity of the chondroblasts is progressively reduced with age and sedentary habits. Joint pain sets in, this in turn reduces mobility causing disuse atrophy of the

supporting muscles leading to increased loading and the cartilage degenerates further and thus a negative cycle sets in. Hence, the earlier the disease is diagnosed and treated, the greater is the effectiveness in the activation and regeneration of the cartilage.

RFQMR stimulates the chondrocytes and initiates the regeneration process, reduces pain and increases mobility of the joint, thus reversing the negative cycle. This study demonstrates that use of RFQMR treatment for osteoarthritis decreases pain, increases mobility, stability and power of the knee joint and helps normalise the life of an osteoarthritic patient. The patients were followed up after 30 days of the treatment and showed no deterioration in their Knee Scores or pain status.

Conclusion

(a) Younger subjects had earlier subjective and objective relief, which was almost complete at 21 days.

(b) Subjects with lower pain scores (i.e. more pain) showed greater subjective improvements.

(c) No gender difference to treatment was seen.

(d) No significant difference in status at the end of treatment and at one month was noted.

(e) Exposure of the knee cartilage to RFQMR is an effective method of treatment and can be a new line of treatment for osteoarthritis.

References

1. Freeman N. Biological and clinical effects of low frequency electric and magnetic fields, Australias, Phys and Engl Sci Med 1980; 3: 182-192.
2. Ryaby JT, Magee FP, Weinstein A. The effect of combined AC/DC magnetic fields on resting articular cartilage metabolism. Proceedings of the I[st] World Congress for electricity and magnetism in biology and medicine. Orlando, Fl, 1992; Jun 14-19.
3. Gabriel SE, Crowson CS, Campion M E, O'Fallon WM. Direct medical costs unique to patients with arthritis. Journal of Rheumatology 1997; 24:719.
4. Li K.H. Physical Basis of coherent radiations from bio molecules, in: Proc. I[st] Intl. Symp. on photon Emission from Biological Systems; 1987 63-95; Warsaw, Poland.
5. Rubik B, Bems S. Symposium explores mechanisms for ELE electromagnetic Bio effects. Frontier Perspectives, 1991;2(2): 1-24.
6. Goodman R, Henderson AS. Transcriptions and translations in cells exposed to extremely low frequency electromagnetic fields. Bioelectrochem. Bioenerget 1991;25: 335-355.
7. Ito H, Bassett CAL. Effect of weak pulsing electromagnetic fields on neural regeneration in the rat. Clinical Orthop and Related Research 1983;181:283-290.
8. Osborn KD, Trippel SB, Mankin HJ. Growth factor stimulation of adult articular cartilage. J Orthop Res 1989;7:35.
9. Neumann E. Membrane electroporation: Toward a molecular mechanism. Proceedings of the I[st] World Congress for electricity and magnetism in biology and medicine. Orlando, Fl, 1992; Jun 14-19.
10. Smith CW, Bests. Electromagnetic Man, JM Dent & Sons, London, 1989.
11. Wallach DFH. in Biological membranes, Vol. II, D. Chapman, DFN. Wallach eds, Acad Press, London,1973; 253.
12. Guyton AC. Textbook of Medical Physiology, WB Saunders Comp, Philadelphia, 1976.
13. Mouneimney Y. Electroinsertion of proteins into membranes: A novel approach to the study of membrane receptors, Harvard Univ. USA. Electricity and magnetism in biology and medicine. San Francisco Press, Inc., USA, 1992.
14. Guzelsu N, Walsh WR. Streaming potential in intact wet bone. J Biomech 1990; 23: 673-85.
15. Frank EH, Grodzinsky AL. A continuum model of cartilage electrokinetics and correlation with experiments. J Biomech 1987; 20: 629-39.
16. Gierse, H Breul, R Faensen, M and Markollik R. Pulsed Signal Therapy (PST) stimulates mitosis of human chondrocytes in culture. Proceedings of Tenth International Conference of Biomedical Engineering; 2004, 473-474; Singapore.
17. Trock DH, Bollet AJ, Dyer RH Jr, Fielding LP, Miner WK, Markoll R. A Double blind trial of the clinical effects of pulsed electromagnetic fields in osteoarthritis. J Rheumatol 1993; 20:456-60.
18. Insall JN, Dorr LD, Scott RD, Scott WN. Rationale of the Knee Society Clinical Rating System Clin Orthop. 1989 ; 248: 13-14.

ISSN 0970-6666

Published biannually by the
INDIAN SOCIETY OF AEROSPACE MEDICINE

Edited & Published by Air Commodore JS Kulkarni for Indian Society of Aerospace Medicine
Designed & Printed by Sathyasri Printers Pvt. Ltd., Bangalore - 560 018 Tel.: 080 - 6525736, 080-6506023

CENTRE FOR ADVANCED RESEARCH & DEVELOPMENT (CARD)
"S-CARD CAMPUS", Seegehalli Main Road, Virgonagar Post,
Bangalore – 560 049.
Ph: 080-25614879, 25614880, Fax: 080-25614878

THE EFFICACY OF ROTATIONAL FIELD QUANTUM NUCLEAR MAGNETIC RESONANCE (RFQMR) IN TISSUE REGENERATION OF CARTILAGE CELLS

Preliminary (pre- exposure) Assessment Protocol for Treatment Schedules Analysis

Tissue Type: _____ **Exposure Days** 21 days **Hr/Exp.** ½ hr.

A. Biographic Data:

Sl. No: DL-047 **Name:** Mrs. Manorama Shenoy

Age: 75 **Gender:** Female

Address: 21/9, M.G. Road,
Bangalore - 560001
Ph: 25584484

Profession: House wife **Height:** 152cms **Weight:** 57kgs

Hip/ Waist Ratio: 94/75

B. Clinical Data:

Affected joint/joints: Both knees **Duration:** 8yrs

Family history of arthritis:
(Genetic Predisposition) Nil

- **Primary (parents, siblings etc)**
- **Secondary (parents, siblings)**
- **Thesauri (Cousins)**

Present Medication: - Paracetemol SOS

Physical Examination:

BP: 166/79 mm Hg **Pulse:** 88/mts Reg.

C.1 Local: Examination of the affected joint/s

Deformity: Yes [ ] No [✓]

Tenderness: Yes [ ] No [✓]

Movements: Passive [No pain] Active [No pain]

D. Radiological Investigation:

D.1. x- ray (both knees- standing preferably with equal weight on both knees):

AP [✓] **Lateral** [✓] **Skyline** [✓]

D.1.1. Cartilage thickness (Left) Joint Space/2)	0.7 mm	**Cartilage thickness (Right)**	1.2 mm
D.1.2. Average Skin to Target distance(Left)	NA	**Average Skin to Target distance (Right)**	NA

E. QMR Exposure:

E.1.	**Date of commencement of exposure**	25 May '05
E.2.	**Time Schedule**	2.30 - 3 PM
E.3.	**Period of Exposure per day**	30 mts
E.4.	**Date of completion of exposure**	14 June '05

F. Adverse reaction (if any) after Commencement of Exposure **Seen after** _____ **Exposures**

Local: Nil

Systemic: Nil.

Type of Reactions:

Nil.

G. **Assessment Questionnaire:**

Thank you for taking time to help us better understand how your knee problem affects your daily life.

Please circle the answer that best describes your knee:

H.1. How much pain do you have when you are walking?

- None
- (•) Mild or Occasional
- Moderate
- Severe

H.2. How much pain does your knee cause when going up and down stairs?

- None
- (•) Mild or Occasional
- Moderate
- Severe

H.3. How much pain does your knee cause when you are at rest?

- (•) Mild
- Moderate
- Severe
- Symptomatic plus objective

H.4. How does your knee affect your walking ability?

- I can walk unlimited distances
- (•) I can walk 2 to 4 Kms
- I can walk 1 to 2 Kms
- I can walk 200 to 1000 mts
- I can walk less than 200 mtrs
- I cannot walk at all.

H.5. How do you go up stairs?

- I go up stairs normally one foot in front of the other.
- (•) I use the handrail for balance.
- I use the handrail to pull myself up.
- I cannot climb stairs.

H.6. How do you go down stairs?

- I go down stairs normally one foot in front of the other.
- I use the handrail for balance.
- (•) I use the handrail to support myself.
- I cannot come down stairs.

H.7. How do you get out of a chair?

- (•) I get out of a chair normally without support.
- I use the armrests for balance.
- I use the armrests for push myself.
- I cannot get out of a chair.

H.8. What type of support do you use when walking?

- (•) None
- Cane
- Crutches
- Walker

Clinical Assessment

	R	L
9. Range of Motion		
•	120 Degrees	124 Degrees
10. Extension Lag		
•	12 Degrees	10 Degrees
11. Flexion Contracture		
•	100 Degrees	100 Degrees
12. Medial/ Lateral Stability		
•	2mm 0- 5 mm	2 mm 0-5 mm
•	5- 10 mm	5- 10 mm
•	> 10 mm	> 10 mm
13. Anterior/ Posterior Stability		
•	1 mm 0- 5 mm	1 mm 0- 5 mm
•	5- 10 mm	5- 10 mm
•	> 10 mm	> 10 mm
14. Alignment		
•	0 Degrees	0 Degrees

Quality of life Assessment (Preliminary)

By ticking one (I) square per line, please indicate how true each statement has been for you during the past 7 days.

	Not at all	A little bit	Some what	Quit a bit	Very much
1.1. Physical Well Being:					
1.1.1. I feel lack of energy	✓				
1.1.2. Because of my knee condition I have trouble meeting the needs of my family:		✓			
1.1.3 I feel very ill:	✓				
1.1.4. I am forced to spend time in bed:		✓			
1.2. Emotional well being:					
1.2.1 I feel sad	✓				
1.2.2 I feel nervous	✓				
1.2.3 I worry that my condition will get worse					✓
1.2.4 I am depressed	✓				
J.1 Functional well being:					
J.1.1 I am able to work (including work at home)	✓				
J.1.2. My work (including work at home) is fulfilling		✓			
J.1.3. I am able to enjoy life		✓			
J.1.4. I am sleeping well					✓
J.1.5 I am content with the quality of my life right now		✓			

Final Assessment:

Total Pain Score _____
Physical Well Being Score_____
Emotional Well Being Score_____
Functional Well Being Score_____

Remarks:

Manohar. V Shetty

Patients Signature | Co-Invest

14.6.05

Date | Name of the principle Investigator | Signature

14 Jun 05

Date | Name of the Co-Investigator | Signature

Centre for Advanced Research and Development (CARD)

S-CARD CAMPUS, Bangalore - 49

C No: 010

Knee Society Rating Analysis

Name: Mrs.Manorama Shenoy Age: 75 Yrs Id Code: 47

Gender: Female Height: 152 Cms Weight: 57 Kgs BSA: 2 Sqm

Assessment	Max.Score	Pre Treatment		Post Treatment	
		L	R	L	R
Pain	50	35	35	30	30
ROM	25	16	15	14	14
Stability					
A. Medial/Lateral	15	5	5	5	5
B. Anterior/Posterior	10	10	10	10	10
Total Knee Score	100	66	65	59	59
Total Functional Score	100	77	72	69	69

L - Left Knee ; R - Right Knee

Assessment by

Investigator

RAW DATA FOR REGENERATION (osteoarthritis) CLINICAL TRIAL

Ref: 081104_PatDat_Osteo

ID#	Treatment Date	Name	Age	Gender	Cart Before L	Cart Before R	Cart After L	Cart After R	Delta_L	Delta_R	Delta_B	%Delta_L	%Delta_R	%Delta_B	Height	Weight	PP_L	PP_R	PA_L	PA_R	RP_L	RP_R	RA_L	RA_R	SPM_L	SPM_R	SAM_L	SAM_R	SPA_L	SPA_R	SAA_L	SAA_R	KS_PL	KS_PR	KS_AL	KS_AR	LP_TFS	RP_TFS	LA_TFS	RA_TFS
1	5/21/2005	Concealed	73	M	0.9	0.8	1.1	0.9	0.2	0.1	0.3	0.22	0.13	0.27	160	49	0	0	35	35	15	15	18	18	5	5	10	10	10	10	10	10	30	30	73	73	71	71	95	95
5	5/21/2005	Concealed	65	F	0.7	0.7	0.6	0.9	-0.1	0.2	0.1	-0.14	0.29	0.17	152	54	25	25	30	30	12	9	12	11	10	5	5	5	10	10	10	10	57	49	57	56	62	67	66	69
6	5/21/2005	Concealed	56	F	1.1	0.9	0.6	0.6	-0.5	-0.3	-0.8	-0.45	-0.33	-1.33	147	64	0	0	0	0	15	16	14	14	10	10	10	10	10	10	10	10	35	36	34	34	-5	0	0	0
7	5/16/2005	Concealed	64	F	1.9	0.8	1.9	1.1	0	0.3	0.3	0.00	0.38	0.16	155	56	0	0	35	35	14	14	16	16	5	5	5	5	10	10	10	10	29	29	66	66	44	39	30	24
8	5/21/2005	Concealed	62	F	0.6	0.7	1.1	0.9	0.5	0.2	0.7	0.83	0.29	0.64	148	66	10	10	0	0	16	16	16	16	5	5	5	10	10	10	10	10	41	41	31	36	65	63	79	79
9	5/21/2005	Concealed	66	F	1.9	2.3	1.9	2.3	0	0	0	0.00	0.00	0.00	154	56	15	15	35	35	16	15	16	16	5	5	10	10	10	10	10	10	46	45	71	71	57	55	92	92
10	5/21/2005	Concealed	75	F	0.7	1.2	1.2	1.1	0.5	-0.1	0.4	0.71	-0.08	0.33	152	57	35	35	45	45	16	15	15	15	5	5	5	5	10	10	10	10	66	65	75	75	77	72	45	45
12	5/27/2005	Concealed	70	F	0.9	0.9	1.1	1.1	0.2	0.2	0.4	0.22	0.22	0.36	157	77	10	10	25	25	14	16	16	16	5	10	10	10	10	10	10	10	39	46	61	61	38	45	25	25
13	5/27/2005	Concealed	72	F	0.7	0.7	0.7	0.6	0	-0.1	-0.1	0.00	-0.14	-0.14	139	57	0	0	10	10	14	13	14	14	5	5	10	10	10	10	10	10	29	28	44	44	59	54	67	64
14	5/26/2005	Concealed	81	F		0.8		0.7	0	-0.1	-0.1		-0.13		148	67	15	15	15	15	11	12	12	13	10	10	10	10	10	10	10	10	46	47	47	48	38	28	42	37
15	5/26/2005	Concealed	80	M	0.7	0.6	0.7	0.7	0	0.1	0.1	0.00	0.17	0.14	175	74	0	5	15	15	16	16	16	16	5	5	5	5	10	10	10	10	31	36	46	46	11	11	38	15
17	5/28/2005	Concealed	65	M	0.7	0.7	0.9	0.9	0.2	0.2	0.4	0.29	0.29	0.44	172	85	0	0	15	15	14	16	15	16	10	5	5	5	10	10	10	10	34	31	45	46	81	76	66	66
20	5/25/2005	Concealed	70	F	0.6	0.8	0.6	0.9	0	0.1	0.1	0.00	0.13	0.17	140	92	20	20	25	25	12	14	13	14	5	5	10	5	10	10	10	10	47	49	58	54	17	22	25	30
24	6/11/2005	Concealed	68	M	0.8	0.8	0.7	0.6	-0.1	-0.2	-0.3	-0.13	-0.25	-0.43	161	75	20	20	0	0	16	16	16	17	5	5	10	5	10	10	10	10	51	51	36	32	72	72	62	62
30	6/11/2005	Concealed	29	M	2.3	1.9	2.5	2.1	0.2	0.2	0.4	0.09	0.11	0.16	186	70	30	30	35	35	17	17	17	18	5	5	5	5	10	10	10	10	62	62	67	68	100	100	100	100
33	6/11/2005	Concealed	78	M	0.7	0.7	0.9	0.9	0.2	0.2	0.4	0.29	0.29	0.44	165	75	0	0	15	15	14	14	16	15	10	10	10	10	10	10	10	10	34	34	51	50	50	45	80	75
35	6/17/2005	Concealed	69	F	0.8	0.8	0.9	0.9	0.1	0.1	0.2	0.13	0.13	0.22	145	65	15	15	10	10	14	11	16	15	10	10	10	10	10	10	10	10	49	46	46	45	33	18	28	28
38	6/16/2005	Concealed	71	M	0.3	0.3	0.7	0.7	0.4	0.4	0.8	1.33	1.33	1.14	158	77	15	15	15	15	14	15	16	16	10	10	10	10	10	10	10	10	49	50	51	51	52	52	54	59
41	6/17/2005	Concealed	63	M	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	168	62	0	0	15	15	16	15	16	15	10	10	10	10	10	10	10	10	36	35	51	50	45	45	59	59
42	6/17/2005	Concealed	80	F	0.7	0.7	0.9	0.9	0.2	0.2	0.4	0.29	0.29	0.44	147	58	0	0	15	15	12	14	14	15	10	10	5	5	10	10	10	10	32	34	44	45	33	28	33	33
43	6/17/2005	Concealed	67	M	0.7	0.9	0.9	1.1	0.2	0.2	0.4	0.29	0.22	0.44	165	76	15	15	15	15	14	14	14	15	10	10	10	10	10	10	10	10	49	49	49	50	77	72	81	81
44	6/17/2005	Concealed	73	F	0.6	0.5	0.9	0.7	0.3	0.2	0.5	0.50	0.40	0.56	148	78	0	0	10	10	14	14	15	14	10	10	10	10	10	10	10	10	34	34	45	44	58	58	43	43
45	6/16/2005	Concealed	65	F	0.7	0.6	0.9	0.8	0.2	0.2	0.4	0.29	0.33	0.44	155	83	0	0	15	15	15	12	16	14	10	10	10	10	10	10	10	10	35	32	51	49	92	87	40	35
48	7/1/2005	Concealed	51	F	0.6	0.3	0.5	0.9	-0.1	0.6	0.5	-0.17	2.00	1.00	160	60	10	0	15	15	16	16	17	17	10	10	10	10	10	10	10	10	46	36	52	52	42	42	70	70
49	7/5/2005	Concealed	62	M	0.9	0.8	1.0	1.2	0.1	0.4	0.5	0.11	0.50	0.50	171	76	0	0	15	15	15	15	15	17	5	10	5	5	10	10	10	0	30	35	45	37	60	65	84	89
50	7/2/2005	Concealed	76	M	0.6	0.4	0.8	0.8	0.2	0.4	0.6	0.33	1.00	0.75	170	73	10	10	0	0	15	16	14	15	10	10	10	10	10	10	10	10	45	46	34	35	18	18	27	25
56	7/1/2005	Concealed	72	F	0.6	0.3	1.1	0.7	0.5	0.4	0.9	0.83	1.33	0.82	174	79	10	10	45	45	15	15	17	17	10	5	5	5	10	10	10	10	45	40	77	77	27	32	59	59
57	7/8/2005	Concealed	66	M	0.6	0.4	0.8	0.7	0.2	0.3	0.5	0.33	0.75	0.63	167	66	15	15	10	10	13	14	13	14	10	10	10	10	10	10	10	10	48	49	43	44	10	15	10	10
58	7/7/2005	Concealed	58	M	0.6	0.4	0.9	0.9	0.3	0.5	0.8	0.50	1.25	0.89	150	65	10	10	10	10	11	12	12	14	10	10	5	5	10	10	10	10	41	42	37	39	10	10	-5	-5
59	6/28/2005	Concealed	80	F	0.7	0.9	1.1	1.1	0.4	0.2	0.6	0.57	0.22	0.55	148	53	35	35	40	40	12	14	15	16	10	10	10	10	10	10	10	10	67	69	75	76	47	52	46	46
62	7/8/2005	Concealed	69	F	0.4	0.6	0.7	1.1	0.3	0.5	0.8	0.75	0.83	1.14	146	47	0	0	15	0	9	11	13	15	10	10	10	10	10	10	10	10	29	31	48	35	10	10	10	10
63	7/9/2005	Concealed	79	M	0.4	0.6	0.8	0.7	0.4	0.1	0.5	1.00	0.17	0.63	165	70	0	0	0	0	16	15	17	17	5	10	10	10	10	10	10	10	31	35	37	37	43	43	38	48
64	7/9/2005	Concealed	68	F	0.4	0.3	0.8	0.8	0.4	0.5	0.9	1.00	1.67	1.13	151	70	0	0	0	0	14	13	15	16	10	10	10	5	10	10	10	10	34	33	35	31	32	27	36	36
65	7/8/2005	Concealed	55	F	0.6	0.5	0.8	0.8	0.2	0.3	0.5	0.33	0.60	0.63	155	85	5	5	15	15	15	12	16	16	10	10	10	10	10	10	10	10	40	37	51	51	32	27	45	45
66	7/7/2005	Concealed	74	F	0.8	0.8	1.1	1.1	0.3	0.3	0.6	0.38	0.38	0.55	159	70	25	25	35	35	12	11	14	15	5	5	10	5	10	10	10	10	52	51	69	65	35	40	45	45
67	7/7/2005	Concealed	65	F	0.4	0.6	0.7	0.6	0.3	0	0.3	0.75	0.00	0.43	155	65	35	5	45	45	12	13	14	15	10	10	10	10	10	10	10	10	67	38	79	80	56	56	59	59
68	7/22/2005	Concealed	58	F	0.6	0.4	0.7	0.7	0.1	0.3	0.4	0.17	0.75	0.57	164	85	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
69	7/24/2005	Concealed	68	M	0.4	0.3	0.7	0.5	0.3	0.2	0.5	0.75	0.67	0.71	173	90	0	0	15	15	5	14	6	15	10	5	10	5	10	10	10	10	25	29	41	45	13	13	23	23
71	7/22/2005	Concealed	70	M	0.5	0.3	0.7	0.7	0.2	0.4	0.6	0.40	1.33	0.86	159	65	0	0	0	0	16	15	17	16	5	5	10	10	10	10	10	10	31	30	37	36	25	25	30	30
72	7/23/2005	Concealed	82	F	0.8	0.8	1.1	1.1	0.3	0.3	0.6	0.38	0.38	0.55	148	70	0	0	15	15	16	15	17	17	5	5	10	10	10	10	10	10	31	30	52	52	49	44	52	47
73	7/23/2005	Concealed	66	F	0.8	1.0	0.8	0.8	0	-0.2	-0.2	0.00	-0.20	-0.25	148	77	10	10	15	15	14	15	16	16	5	5	5	5	10	10	10	10	39	40	46	46	25	25	32	32
74	7/24/2005	Concealed	55	F	0.4	0.4	0.7	0.7	0.3	0.3	0.6	0.75	0.75	0.86	166	120	0	15	5	10	14	12	15	14	5	5	5	5	10	10	10	10	29	42	35	39	40	40	35	54
76	7/27/2005	Concealed	75	M	0.4	0.3	0.7	0.7	0.3	0.4	0.7	0.75	1.33	1.00	170	65	10	10	35	35	17	16	18	17	5	5	5	5	0	10	10	10	32	41	68	67	89	89	80	80
78	7/22/2005	Concealed	57	M	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	168	74	30	35	40	40	16	16	17	16	5	5	5	5	10	10	10	10	61	66	72	71	64	80	95	95
79	11/23/2005	Concealed	73	F	0.5	0.5	1.1	1.0	0.6	0.5	1.1	1.20	1.00	1.00	145	62	25	25	45	45	14	15	16	15	5	5	10	10	10	10	10	10	54	55	81	80	54	54	28	28
80	7/28/2005	Concealed	75	F	0.3	0.4	0.7	0.7	0.4	0.3	0.7	1.33	0.75	1.00	153	67	5	5	10	10	14	14	16	16	5	5	10	5	10	10	10	10	34	34	46	41	37	32	41	52
81	7/28/2005	Concealed	77	F	0.2	0.3	0.5	0.7	0.3	0.4	0.7	1.50	1.33	1.40	157	58	5	5	15	15	14	15	15	16	5	5	10	5	10	10	10	10	34	35	50	46	56	61	56	59
82	7/28/2005	Concealed	68	M	0.3	0.3	0.7	0.7	0.4	0.4	0.8	1.33	1.33	1.14	169	86	10	10	35	35	13	14	16	16	10	10	10	10	10	10	10	10	43	44	71	71	47	47	75	75
83	7/30/2005	Concealed	47	F	0.3	0.4	0.6	0.6	0.3	0.2	0.5	1.00	0.50	0.83	151	72	0	0	35	35	15	11	16	12	5	5	10	10	10	10	10	10	30	26	71	67	22	32	32	27
84	7/22/2005	Concealed	63	F	0.4	0.6	0.7	0.8	0.3	0.2	0.5	0.75	0.33	0.71	168	70	15	15	20	20	14	14	15	16	5	5	10	10	10	10	10	10	44	44	55	56	46	46	74	74
85	7/31/2005	Concealed	75	M	0.4	0.6	0.8	1.1	0.4	0.5	0.9	1.00	0.83	1.13	164	76	25	25	0	0	14	15	16	16	5	5	10	10	10	10	10	10	54	55	36	36	44	44	28	28
86	7/25/2005	Concealed	66	M	0.4	0.3	0.7	0.7	0.3	0.4	0.7	0.75	1.33	1.00	164	103	0	0	15	15	15	16	16	17	5	5	5	5	10	10	10	10	30	31	46	47	25	25	25	25
88	7/30/2005	Concealed	48	F	0.5	0.6	0.7	0.7	0.2	0.1	0.3	0.40	0.17	0.43	150	79	0	0	15	15	14	14	15	15	5	5	10	10	10	10	10	10	29	29	50	50	22	22	66	66
89	7/27/2005	Concealed	60	M	0.4	0.2	0.7	0.7	0.3	0.5	0.8	0.75	2.50	1.14	166	78	0	0	15	15	15	16	17	18	5	5	10	10	10	10	10	10	30	31	52	53	35	20	44	44
90	7/22/2005	Concealed	59	F	0.7	0.6	0.8	0.8	0.1	0.2	0.3	0.14	0.33	0.38	146	60	15	15	35	35	14	16	16	16	5	5	10	5	10	10	10	10	44	46	71	66	46	46	81	66
91	7/22/2005	Concealed	75	F	0.3	0.6	1.1	0.7	0.8	0.1	0.9	2.67	0.17	0.82	149	65	0	0	15	15	12	12	14	14	10	10	10	10	10	10	10	10	32	32	49	49	20	20	20	25
92	7/29/2005	Concealed	47	F	0.4	0.4	0.7	0.9	0.3	0.5	0.8	0.75	1.25	1.14	154	88	0	0	15	15	12	15	15	17	10	10	10	5	10	10	10	10	32	35	50	47	49	54	56	61
93	8/10/2005	Concealed	67	F	0.7	0.8	0.8	0.9	0.1	0.1	0.2	0.14	0.13	0.25	160	54	20	20	35	35	16	16	16	16	5	5	10	10	10	10	10	10	51	51	71	71	90	95	95	95
94	8/10/2005	Concealed	69	F	0.8	0.7	1.1	1.1	0.3	0.4	0.7	0.38	0.57	0.64	149	80	0	0	0	0	15	15	14	16	5	5	10	5	10	10	10	10	30	30	34	31	55	55	55	55
97	8/10/2005	Concealed	44	F	0.6	0.6	1.1	0.7	0.5	0.1	0.6	0.83	0.17	0.55	149	54	10	10	30	30	16	15	16	16	5	5	10	10	10	10	10	10	41	40	66	66	82	77	97	95
98	8/16/2005	Concealed	60	F	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	154	60	0	0	35	35	14	14	14	15	5	5	10	10	10	10	10	10	29	29	69	70	30	30	56	56
99	8/12/2005	Concealed	59	F	0.7	0.5	0.7	0.7	0	0.2	0.2	0.00	0.40	0.29	157	70	0	0	0	0	15	15	15	16	5	5	10	10	10	10	10	10	30	30	35	36	30	30	51	51
100	8/18/2005	Concealed	57	M	0.7	0.9	1.1	1.1	0.4	0.2	0.6	0.57	0.22	0.55	161	70	0	0	15	15	14	14	13	13	5	5	10	10	10	10	10	10	29	29	48	48	40	40	51	51
101	8/13/2005	Concealed	69	F	0.9	1.1	1.1	1.5	0.2	0.4	0.6	0.22	0.36	0.55	150	90	15	15	35	35	13	15	14	15	5	5	5	10	10	10	10	10	43	45	64	70	-2	3	44	49
102	8/13/2005	Concealed	67	F	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	153	64	35	35	30	30	14	15	14	15	5	5	10	10	10	10	10	10	64	65	64	65	79	84	79	84
103	8/11/2005	Concealed	72	F	0.6	0.7	1.1	1.1	0.5	0.4	0.9	0.83	0.57	0.82	166	73	0	0	0	0	14	15	14	15	5	5	5	5	10	10	10	10	29	30	29	30	35	35	25	25
104	8/17/2005	Concealed	52	F	0.5	0.4	0.7	0.5	0.2	0.1	0.3	0.40	0.25	0.43	167	67	10	10	15	15	15	15	16	16	5	5	5	5	10	10	10	10	40	40	46	46	56	56	59	59
106	8/20/2005	Concealed	67	F	0.7	0.9	1.1	1.1	0.4	0.2	0.6	0.57	0.22	0.55	166	65	5	5	15	15	16	16	16	16	10	10	10	10	10	10	10	10	41	41	51	51	44	39	44	39
107	8/20/2005	Concealed	54	F	0.4	0.4	0.7	0.6	0.3	0.2	0.5	0.75	0.50	0.71	163	80	0	0	15	15	14	15	14	15	5	5	5	5	10	10	10	10	29	30	44	45	35	35	62	62
108	8/20/2005	Concealed	63	F	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	151	73	0	0	45	45	14	14	13	15	5	5	5	10	10	10	10	10	29	29	73	80	70	70	69	72
110	8/22/2005	Concealed	56	F	1.1	1.2	1.3	1.3	0.2	0.1	0.3	0.18	0.08	0.23	157	80	0	0	15	15	15	11	16	12	10	10	10	10	10	10	10	10	35	31	51	47	20	10	25	20
111	8/22/2005	Concealed	62	F	0.3	0.4	0.7	0.7	0.4	0.3	0.7	1.33	0.75	1.00	152	62	10	10	35	35	16	16	16	16	5	5	10	5	10	10	10	10	41	41	71	66	37	32	51	51
112	9/19/2005	Concealed	75	F	0.6	0.9	1.2	1.2	0.6	0.3	0.9	1.00	0.33	0.75	153	72	35	35	35	35	11	11	11	12	10	10	10	10	10	10	10	10	66	66	66	67	40	40	55	70
113	8/12/2005	Concealed	56	F		0.7		0.9	0	0.2	0.2		0.29		151	55	0	0	0	0	16	16	14	15	5	5	10	10	10	10	10	0	31	31	34	25	61	61	46	34
114	8/16/2005	Concealed	73	F	0.7	0.9	1.0	1.4	0.3	0.5	0.8	0.43	0.56	0.80	148	55	10	10	35	35	16	15	16	16	5	5	5	5	10	10	10	10	41	40	66	66	32	32	81	81
115	8/20/2005	Concealed	63	F	0.5	0.4	0.7	0.7	0.2	0.3	0.5	0.40	0.75	0.71	153	69	5	5	15	15	16	16	16	16	5	5	5	5	10	10	10	10	36	36	46	46	54	49	54	49
116	8/18/2005	Concealed	64	F	0.9	0.9	1.1	1.1	0.2	0.2	0.4	0.22	0.22	0.36	158	60	0	0	0	0	15	15	15	16	5	5	10	5	10	10	10	10	30	30	35	31	61	51	69	66
117	8/17/2005	Concealed	63	F	0.5	0.3	0.7	0.7	0.2	0.4	0.6	0.40	1.33	0.86	153	60	0	0	0	0	16	17	16	16	10	10	10	10	10	10	10	10	36	37	36	36	25	25	35	30
118	9/6/2005	Concealed	63	F	0.9	0.5	1.1	0.7	0.2	0.2	0.4	0.22	0.40	0.36	168	78	10	10	10	10	14	12	14	12	5	5	5	5	10	10	10	10	39	37	39	37	59	59	49	49
119	9/9/2005	Concealed	69	M	0.7	0.7	0.8	0.8	0.1	0.1	0.2	0.14	0.14	0.25	165	70	35	35	35	35	14	15	14	15	5	10	10	5	10	10	10	10	64	70	69	65	81	81	69	69
120	9/9/2005	Concealed	64	F	0.8		1.1		0.3	0	0.3	0.38		0.27	171	64	10	10	30	30	13	12	14	13	10	5	10	10	10	10	10	10	43	37	64	63	69	69	69	72
122	9/6/2005	Concealed	71	M	0.9	0.7	1.1	1.1	0.2	0.4	0.6	0.22	0.57	0.55	170	53	15	15	20	20	16	16	16	16	10	10	10	10	10	10	10	10	51	51	56	56	62	62	62	65
123	9/3/2005	Concealed	75	F	1.2	0.5	1.4	0.8	0.2	0.3	0.5	0.17	0.60	0.36	153	65	25	35	15	15	15	16	16	16	10	5	10	5	10	10	10	10	60	66	51	46	27	32	32	32
124	9/5/2005	Concealed	66	F	1.3	1.1	1.5	1.5	0.2	0.4	0.6	0.15	0.36	0.40	149	65	10	10	10	10	13	12	14	14	5	10	5	10	10	10	10	10	38	42	39	44	65	62	56	56
125	9/8/2005	Concealed	70	M	0.1	0.1	0.7	0.7	0.65	0.65	1.3	13.00	13.00	1.86	171	68	10	10	20	20	14	14	14	14	10	10	10	10	10	10	10	10	44	44	54	54	44	44	56	51
126	9/6/2005	Concealed	65	F	0.7	0.9	0.9	1.1	0.2	0.2	0.4	0.29	0.22	0.44	155	62	0	0	15	15	15	15	15	15	10	10	10	10	10	10	10	10	35	35	50	50	44	44	56	56
127	9/8/2005	Concealed	60	F	0.7	0.7	0.4	0.5	-0.3	-0.2	-0.5	-0.43	-0.29	-1.25	150	56	0	0	15	15	13	14	13	14	10	10	10	10	10	10	10	10	33	34	48	49	-10	5	18	23
128	9/6/2005	Concealed	68	F	0.9	0.9	1.1	1.1	0.2	0.2	0.4	0.22	0.22	0.36	158	62	15	15	20	20	15	15	16	15	10	10	10	10	10	10	10	10	50	50	56	55	51	56	51	56
129	9/9/2005	Concealed	41	F	0.8	0.8	1.0	0.9	0.2	0.1	0.3	0.25	0.13	0.30	162	61	10	10	25	25	15	14	16	17	5	5	10	10	10	10	10	10	40	39	61	62	52	52	45	45
130	9/11/2005	Concealed	52	F	1.0	1.2	1.2	1.5	0.2	0.3	0.5	0.20	0.25	0.42	156	70	10	10	15	15	16	15	16	16	5	5	10	10	10	10	10	10	41	40	51	51	56	56	72	72
131	9/10/2005	Concealed	55	F	0.9	0.9	1.1	1.1	0.2	0.2	0.4	0.22	0.22	0.36	146	56	0	0	10	10	15	14	16	14	5	5	10	10	10	10	10	10	30	29	46	44	50	50	25	25
132	9/12/2005	Concealed	70	M	0.7	0.7	0.9	0.8	0.2	0.1	0.3	0.29	0.14	0.33	175	68	15	15	15	15	15	15	15	16	10	10	10	10	10	10	10	10	50	50	50	51	20	25	25	28
133	9/12/2005	Concealed	69	M	0.7	0.9	0.8	1.0	0.1	0.1	0.2	0.14	0.11	0.25	171	81	0	0	15	15	13	14	14	15	10	10	10	10	10	10	10	10	33	34	49	50	42	42	52	52
134	9/14/2005	Concealed	73	F	0.7	0.6	1.1	0.8	0.4	0.2	0.6	0.57	0.33	0.55	151	60	0	0	25	25	11	12	12	13	10	10	10	10	10	10	10	10	31	32	57	58	50	55	39	20
136	9/11/2005	Concealed	66	F	0.8	0.8	1.1	1.1	0.3	0.3	0.6	0.38	0.38	0.55	150	74	15	15	20	20	14	16	14	16	5	5	10	10	10	10	10	10	44	46	54	56	65	75	75	78
137	9/14/2005	Concealed	62	F	0.6	0.6	0.8	0.7	0.2	0.1	0.3	0.33	0.17	0.38	155	71	15	15	40	40	14	14	15	15	5	5	10	0	10	10	10	10	44	44	75	65	59	46	77	74
139	9/13/2005	Concealed	68	F	0.9	1.1	1.3	1.2	0.4	0.1	0.5	0.44	0.09	0.38	157	58	0	0	0	0	12	14	14	14	10	10	10	10	0	0	10	0	22	24	34	24	10	10	10	10

140	9/13/2005	Concealed	55	F	0.8	0.9	0.9	1.0	0.1	0.1	0.2	0.13	0.11	0.22	158	84	5	0	0	0	12	13	12	14	5	0	0	0	0	0	0	0	22	13	12	14	18	18	35	28
141	9/13/2005	Concealed	51	F	0.6	0.6	0.8	0.7	0.2	0.1	0.3	0.33	0.17	0.38	156	58	0	15	35	30	16	16	16	17	5	5	10	10	0	0	0	0	21	36	61	57	53	53	75	75
143	10/1/2005	Concealed	58	F	0.8	0.9	1.1	1.1	0.3	0.2	0.5	0.38	0.22	0.45	172	83	0	0	20	20	14	16	14	16	0	0	0	0	0	0	0	0	14	16	34	36	51	41	61	56
144	9/26/2005	Concealed	66	F	0.6	0.7	0.9	0.9	0.3	0.2	0.5	0.50	0.29	0.56	159	78	15	15	15	15	12	12	13	15	0	0	0	0	0	0	0	0	27	27	28	30	46	49	46	46
145	9/26/2005	Concealed	64	F	0.7	0.7	0.9	0.9	0.2	0.2	0.4	0.29	0.29	0.44	166	69	10	10	15	15	15	15	16	17	0	0	0	0	0	0	0	0	25	25	31	32	25	28	35	38
146	9/26/2005	Concealed	76	M	0.8	0.7	1.0	0.8	0.2	0.1	0.3	0.25	0.14	0.30	178	98	0	0	0	0	14	15	16	16	0	0	0	0	0	0	0	0	14	15	16	16	15	15	10	10
147	9/27/2005	Concealed	46	F	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	167	78	0	0	15	15	16	15	16	16	0	0	0	0	0	0	0	0	16	15	31	31	10	25	27	42
148	9/30/2005	Concealed	60	M	0.7	0.7	1.1	0.9	0.4	0.2	0.6	0.57	0.29	0.55	178	98	0	0	15	15	14	15	15	16	0	0	0	0	0	0	0	0	14	15	30	31	25	25	52	45
149	9/30/2005	Concealed	56	F	0.8	0.8	1.1	1.1	0.3	0.3	0.6	0.38	0.38	0.55	162	87	0	0	0	0	12	11	14	12	0	0	0	0	0	0	0	0	12	11	14	12	20	15	25	25
150	9/29/2005	Concealed	60	F	0.7	0.9	0.9	1.1	0.2	0.2	0.4	0.29	0.22	0.44	160	79	0	0	15	30	15	16	16	16	0	0	0	0	0	0	0	0	15	16	31	46	49	49	59	49
151	10/1/2005	Concealed	74	M	0.7	0.7	0.8	0.8	0.1	0.1	0.2	0.14	0.14	0.25	173	75	0	0	10	15	14	14	15	15	0	10	5	10	0	0	0	0	14	24	30	40	20	23	23	23
152	9/27/2005	Concealed	67	F	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	155	80	15	15	45	45	14	15	15	16	5	0	0	0	0	0	0	0	34	30	60	61	52	49	62	62
155	10/3/2005	Concealed	60	F	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	152	61	30	30	45	45	16	14	16	14	0	0	0	0	0	0	0	0	46	44	61	59	54	59	69	84
156	10/3/2005	Concealed	45	M	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	172	83	5	5	15	15	12	14	13	16	0	0	0	0	0	0	0	0	17	19	28	31	18	23	28	33
159	10/3/2005	Concealed	62	F	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	152	78	10	10	0	0	16	15	16	15	0	0	0	0	0	0	0	0	26	25	16	15	59	59	59	44
160	10/2/2005	Concealed	65	F	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	152	80	5	10	10	10	11	13	12	14	0	0	0	0	0	0	0	0	16	23	22	24	20	35	70	75
163	10/4/2005	Concealed	52	F	0.7	0.8	1.1	1.1	0.4	0.3	0.7	0.57	0.38	0.64	147	68	0	0	30	30	16	16	16	17	0	0	0	0	0	0	0	0	16	16	46	47	20	25	27	32
164	10/28/2005	Concealed	65	F	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	155	63	10	10	30	30	10	9	10	9	0	0	0	0	0	0	0	0	20	19	40	39	49	37	40	42
165	11/2/2005	Concealed	65	M	0.8	0.9	0.8	0.9	0	0	0	0.00	0.00	0.00	168	75	30	30	15	15	16	16	16	16	0	0	0	0	0	0	0	0	46	46	31	31	84	84	87	87
166	10/26/2005	Concealed	70	F	0.7		1.1		0.4	0	0.4	0.57		0.36	161	80	10	10	15	10	14	12	15	12	0	0	0	0	0	0	0	0	24	22	30	22	40	38	52	42
168	10/27/2005	Concealed	73	F	0.6	0.4	0.8	0.5	0.2	0.1	0.3	0.33	0.25	0.38	150	87	0	0	15	15	10	10	10	10	0	0	0	0	0	0	0	0	10	10	25	25	8	8	31	41
169	10/3/2005	Concealed	43	F	0.7	0.7	0.8	0.9	0.1	0.2	0.3	0.14	0.29	0.38	155	71	40	40	30	30	15	16	16	16	0	0	0	0	0	0	0	0	55	56	46	46	49	49	86	86
171	11/1/2005	Concealed	61	F	0.7	0.5	0.9	0.7	0.2	0.2	0.4	0.29	0.40	0.44	152	69	0	0	15	15	10	15	12	16	0	0	0	0	0	0	0	0	10	15	27	31	10	15	34	39
172	9/27/2005	Concealed	59	F	0.7	0.7	0.9	0.9	0.2	0.2	0.4	0.29	0.29	0.44	155	73	0	0	10	10	14	14	15	14	0	0	0	0	0	0	0	0	14	14	25	24	49	49	49	49
173	10/30/2005	Concealed	57	F	0.7	0.7	0.9	0.9	0.2	0.2	0.4	0.29	0.29	0.44	151	91	10	10	35	20	15	12	16	14	0	0	0	0	0	0	0	0	25	22	51	34	60	55	69	69
174	10/29/2005	Concealed	62	F	0.7	0.7	0.9	0.9	0.2	0.2	0.4	0.29	0.29	0.44	159	62	30	30	35	35	16	16	16	16	0	0	0	0	0	0	0	0	46	46	51	51	86	86	84	84
175	11/4/2005	Concealed	68	M	0.6	0.6	0.8	0.7	0.2	0.1	0.3	0.33	0.17	0.38	173	105	0	0	20	20	14	14	15	15	0	0	0	0	0	0	0	0	14	14	35	35	10	15	47	46
176	11/4/2004	Concealed	45	M	0.7	0.7	1.4	1.1	0.7	0.4	1.1	1.00	0.57	0.79	161	62	0	0	25	10	16	16	16	16	0	0	0	0	0	0	0	0	16	16	41	26	86	86	81	81
177	11/4/2004	Concealed	47	M	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	166	76	0	0	30	15	16	16	4	16	0	0	0	0	0	0	0	0	16	16	34	31	75	75	75	80
178	11/3/2005	Concealed	72	M	0.7	0.7	0.8	0.9	0.1	0.2	0.3	0.14	0.29	0.38	153	100	15	15	30	30	13	14	14	15	0	0	0	0	0	0	0	0	28	29	44	45	17	25	26	41
179	11/4/2005	Concealed	73	M	0.7	0.7	1.0	0.9	0.3	0.2	0.5	0.43	0.29	0.50	165	84	0	0	30	30	15	16	16	16	0	0	0	0	0	0	0	0	15	16	46	46	59	59	49	54
180	10/31/2005	Concealed	50	M	0.9	0.9	1.1	1.1	0.2	0.2	0.4	0.22	0.22	0.36	174	99	30	30	35	35	15	16	16	16	0	0	0	0	0	0	0	0	45	46	51	51	60	60	70	70
181	11/4/2005	Concealed	62	F	0.4	0.4	0.6	0.6	0.2	0.2	0.4	0.50	0.50	0.67	169	107	15	15	30	30	14	13	15	15	0	0	0	0	0	0	0	0	29	28	45	45	20	18	28	28
182	11/3/2005	Concealed	52	F	0.5	0.5	0.7	0.7	0.2	0.2	0.4	0.40	0.40	0.57	156	83	0	0	30	35	13	12	14	14	0	0	0	0	0	0	0	0	13	12	44	49	32	27	52	32
184	11/1/2005	Concealed	43	F	0.8	0.7	0.9	0.9	0.1	0.2	0.3	0.13	0.29	0.33	172	83	35	35	35	35	16	16	16	16	0	0	0	0	0	0	0	0	51	51	51	51	80	80	87	87
186	11/19/2005	Concealed	68	F	0.5	0.4	1.0	0.9	0.5	0.5	1	1.00	1.25	1.00	155	83	15	15	30	30	15	14	15	15	0	0	0	0	0	0	0	0	30	29	45	45	49	49	69	69
187	11/18/2005	Concealed	72	M	0.5	0.5	0.9	0.7	0.4	0.2	0.6	0.80	0.40	0.67	165	72	15	30	35	40	14	14	15	15	0	0	0	0	0	0	0	0	29	44	50	55	66	66	56	66
188	11/23/2005	Concealed	54	F	0.8	0.6	0.9	0.9	0.1	0.3	0.4	0.13	0.50	0.44	147	65	0	0	20	20	14	11	14	11	0	0	0	0	0	0	0	0	14	11	34	31	37	27	19	37
189	11/21/2005	Concealed	62	F	0.4	0.4	1.1	0.9	0.7	0.5	1.2	1.75	1.25	1.09	151	65	10	10	10	10	11	10	12	11	0	0	0	0	0	0	0	0	21	20	22	21	31	56	56	56
190	11/18/2005	Concealed	58	M	0.4	0.4	0.7	0.7	0.3	0.3	0.6	0.75	0.75	0.86	158	66	35	35	35	35	15	16	16	18	0	0	0	0	0	0	0	0	50	51	51	53	74	74	39	29
191	11/17/2005	Concealed	75	F	0.7	0.7	0.9	0.9	0.2	0.2	0.4	0.29	0.29	0.44	157	72	0	0	0	0	15	13	15	14	0	0	0	0	0	0	0	0	15	13	15	14	20	10	28	23
192	11/22/2005	Concealed	69	M	0.5	0.5	0.7	0.7	0.2	0.2	0.4	0.40	0.40	0.57	160	72	0	0	15	15	14	15	15	16	0	0	0	0	0	0	0	0	14	15	30	31	46	51	40	40
193	11/22/2005	Concealed	62	F	0.5	0.5	0.7	0.7	0.2	0.2	0.4	0.40	0.40	0.57	141	68	35	35	45	45	15	16	16	16	0	0	0	0	0	0	0	0	50	51	61	61	80	80	55	70
195	11/24/2005	Concealed	64	M	0.8	0.7	0.8	0.8	0	0.1	0.1	0.00	0.14	0.13	172	65	30	30	30	30	16	12	17	13	0	0	0	0	0	0	0	0	46	42	47	43	75	75	57	57
196	11/25/2005	Concealed	52	F	0.4	0.4	0.7	0.7	0.3	0.3	0.6	0.75	0.75	0.86	148	56	30	30	30	30	14	15	15	16	0	0	0	0	0	0	0	0	44	45	45	46	61	61	74	74
197	11/26/2005	Concealed	76	M	0.7	0.8	0.7	0.8	0	0	0	0.00	0.00	0.00	161	76	15	15	15	15	12	15	14	16	0	0	0	0	0	0	0	0	27	30	29	31	32	37	50	38
199	11/26/2005	Concealed	66	F	0.7	0.7	0.9	0.9	0.2	0.2	0.4	0.29	0.29	0.44	149	64	0	0	30	30	10	11	12	11	0	0	0	0	0	0	0	0	10	11	42	41	39	39	32	32
200	11/24/2005	Concealed	64	F	0.5	0.7	0.9	0.9	0.4	0.2	0.6	0.80	0.29	0.67	148	84	0	0	30	30	14	12	15	12	0	0	0	0	0	0	0	0	14	12	45	42	27	37	49	49
201	11/25/2005	Concealed	73	F	0.7	0.7	0.9	0.9	0.2	0.2	0.4	0.29	0.29	0.44	156	59	15	15	15	15	14	14	14	14	0	0	0	0	0	0	0	0	29	29	29	29	32	32	56	56
202	11/26/2005	Concealed	70	F	0.7	0.7	1.0	0.9	0.3	0.2	0.5	0.43	0.29	0.50	149	56	0	0	35	35	12	12	13	12	0	0	0	0	0	0	0	0	12	12	48	47	32	32	25	20
204	12/13/2005	Concealed	70	F	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	149	56	0	0	0	0	15	16	16	16	5	5	5	0	0	0	0	0	20	21	21	16	39	39	39	46
205	12/16/2005	Concealed	75	F	0.6	0.6	0.6	0.6	0	0	0	0.00	0.00	0.00	150	67	10	10	10	10	11	9	11	10	5	0	10	0	0	0	0	0	26	19	31	20	15	5	13	13
208	12/7/2005	Concealed	78	M	0.7	0.8	0.9	1.1	0.2	0.3	0.5	0.29	0.38	0.56	173	64	0	0	35	35	17	16	17	16	10	5	0	0	0	0	0	0	27	21	52	51	41	46	49	52
210	12/8/2005	Concealed	56	F	0.8	0.7	1.2	1.1	0.4	0.4	0.8	0.50	0.57	0.67	166	57	0	0	10	10	12	16	16	16	5	5	5	10	0	0	0	0	17	21	31	36	10	48	48	48
212	12/10/2005	Concealed	55	M	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	161	68	15	15	30	30	16	16	17	17	10	5	10	10	10	10	10	10	51	46	67	67	56	56	84	87
213	12/19/2005	Concealed	70	F	0.4	0.4	0.7	0.7	0.3	0.3	0.6	0.75	0.75	0.86	154	60	10	10	0	0	14	16	15	17	0	0	0	0	0	0	0	0	24	26	15	17	44	49	30	30
214	12/20/2005	Concealed	65	M	1.1	0.4	1.4	0.7	0.3	0.3	0.6	0.27	0.75	0.43	165	80	0	0	15	15	14	14	15	15	0	0	0	0	0	0	0	0	14	14	30	30	52	52	52	52
218	12/19/2005	Concealed	65	M	0.4	0.5	0.7	0.8	0.3	0.3	0.6	0.75	0.60	0.86	170	70	15	15	15	15	16	16	16	16	0	0	0	0	0	0	0	0	31	31	31	31	90	90	90	90
220	1/4/2006	Concealed	57	F	0.5	0.7	0.7	0.8	0.2	0.1	0.3	0.40	0.14	0.43	153	64	0	0	0	0	16	15	16	16	0	0	0	0	0	0	0	0	16	15	16	16	65	62	49	46
223	1/3/2006	Concealed	85	M	0.4	0.5	0.7	0.9	0.3	0.4	0.7	0.75	0.80	1.00	174	82	15	15	15	15	14	16	14	16	5	5	5	0	0	0	0	0	34	36	34	31	41	24	44	34
224	1/4/2006	Concealed	64	M	0.7	0.4	1.1	0.6	0.4	0.2	0.6	0.57	0.50	0.55	176	92	10	10	30	30	16	15	16	16	0	0	0	10	0	0	0	0	26	25	46	56	70	55	85	90
225	5/10/2006	Concealed	54	F	0.4	0.7	0.5	0.8	0.1	0.1	0.2	0.25	0.14	0.40	153	51	5	5	5	5	12	11	12	11	10	5	10	0	0	10	0	0	27	31	27	16	20	10	4	17
227	1/3/2006	Concealed	62	F	0.4	0.4	0.8	0.7	0.4	0.3	0.7	1.00	0.75	0.88	155	70	0	0	0	0	16	16	17	17	5	5	5	10	0	0	0	0	21	21	22	27	32	32	28	25
228	12/31/2005	Concealed	69	F	0.6	0.6	0.6	0.6	0	0	0	0.00	0.00	0.00	160	68	10	10	20	20	15	14	16	14	5	10	10	5	0	0	0	0	30	34	46	39	28	33	40	54
229	12/29/2005	Concealed	68	M	0.9	0.9	0.9	0.9	0	0	0	0.00	0.00	0.00	167	70	35	35	35	35	16	15	16	15	0	0	0	0	0	0	0	0	51	50	51	50	90	90	90	90
230	1/3/2006	Concealed	74	M	0.4	0.4	0.7	0.7	0.3	0.3	0.6	0.75	0.75	0.86	167	73	20	10	10	10	15	15	16	16	0	0	0	0	0	0	0	0	35	25	26	26	42	42	39	39
231	1/13/2006	Concealed	58	F	0.8	0.6	1.1	0.8	0.3	0.2	0.5	0.38	0.33	0.45	160	75	10	25	25	25	16	17	17	18	10	5	5	10	10	10	10	10	46	57	57	63	25	20	50	52
234	1/9/2006	Concealed	69	M	0.6	0.7	0.8	0.9	0.2	0.2	0.4	0.33	0.29	0.50	159	81	10	10	5	5	16	16	16	16	5	10	5	0	10	10	10	10	41	46	36	31	81	76	67	67
235	1/9/2006	Concealed	62	F	0.8	0.9	1.0	1.1	0.2	0.2	0.4	0.25	0.22	0.40	159	81	0	0	0	0	15	14	16	16	10	10	5	5	10	10	10	10	35	34	31	31	62	57	39	39
236	1/10/2006	Concealed	64	F	0.6	0.5	0.8	0.7	0.2	0.2	0.4	0.33	0.40	0.50	157	77	15	15	15	15	11	15	14	16	0	0	5	5	10	10	10	10	36	40	44	46	56	56	45	42
237	1/9/2006	Concealed	72	F	0.7	0.5	0.9	0.7	0.2	0.2	0.4	0.29	0.40	0.44	146	70	0	0	10	10	15	17	16	17	5	5	5	10	10	10	10	10	30	32	41	47	20	23	45	45
238	1/7/2006	Concealed	73	F	0.7	0.7	0.8	0.8	0.1	0.1	0.2	0.14	0.14	0.25	163	64	0	0	15	15	16	15	17	16	10	10	5	5	10	10	10	10	36	35	47	46	41	41	66	66
239	1/21/2006	Concealed	62	M	0.8	0.8	0.9	0.9	0.1	0.1	0.2	0.13	0.13	0.22	184	106	15	15	15	15	16	15	16	15	10	5	10	10	10	10	10	10	51	45	51	50	75	80	75	80
240	6/24/2006	Concealed	67	M	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	165	84	15	15	30	30	16	15	17	16	5	5	5	5	10	10	10	10	46	45	62	61	40	35	86	84
241	1/23/2006	Concealed	71	M	0.7	0.7	0.8	1.0	0.1	0.3	0.4	0.14	0.43	0.50	154	68	0	0	0	0	14	15	14	15	5	5	5	5	10	10	10	10	29	30	29	30	25	30	25	25
242	1/27/2006	Concealed	75	M	0.7	0.7	1.0	0.9	0.3	0.2	0.5	0.43	0.29	0.50	168	70	20	5	15	15	15	14	16	15	0	0	0	0	10	10	10	10	45	29	41	40	65	62	69	71
243	1/23/2006	Concealed	55	F	0.7	0.7	1.1	1.1	0.4	0.4	0.8	0.57	0.57	0.73	159	80	10	10	15	15	10	12	8	13	0	0	0	0	10	10	0	10	30	32	23	38	39	39	27	25
244	1/26/2006	Concealed	57	F	0.7	0.7	0.9	0.9	0.2	0.2	0.4	0.29	0.29	0.44	145	81	0	0	15	15	14	14	16	16	0	0	0	0	10	10	10	10	24	24	41	41	15	15	30	30
245	1/24/2006	Concealed	51	F	0.5	0.5	0.7	0.7	0.2	0.2	0.4	0.40	0.40	0.57	153	65	10	10	15	15	16	16	17	16	0	0	5	5	10	10	10	10	36	36	47	46	59	40	64	64
246	1/27/2006	Concealed	70	F	0.9	0.9	1.2	1.0	0.3	0.1	0.4	0.33	0.11	0.33	152	94	0	0	0	0	12	14	14	15	0	0	0	0	10	10	10	10	22	24	24	25	19	19	46	41
247	2/3/2006	Concealed	73	F	0.7	0.7	1.2	1.1	0.5	0.4	0.9	0.71	0.57	0.75	169	70	10	10	25	25	12	14	14	15	0	0	0	0	10	10	10	10	32	34	49	50	25	25	46	46
248	1/27/2006	Concealed	73	F	0.8	0.8	0.9	0.9	0.1	0.1	0.2	0.13	0.13	0.22	153	84	10	10	15	15	14	15	14	16	0	0	0	0	10	10	10	10	34	35	39	41	35	35	52	52
249	1/31/2006	Concealed	66	M	0.4		0.7		0.3	0	0.3	0.75		0.43	170	76	0	0	20	20	12	14	13	14	0	0	0	0	10	10	10	10	22	24	43	44	33	33	37	37
250	2/1/2006	Concealed	58	F	0.7	0.7	0.8	0.9	0.1	0.2	0.3	0.14	0.29	0.38	168	66	10	10	10	10	15	14	16	16	0	0	0	0	10	10	10	10	35	34	36	36	44	42	64	62
251	2/3/2006	Concealed	81	M	0.4	0.4	0.7	0.7	0.3	0.3	0.6	0.75	0.75	0.86	152	72	15	15	45	45	11	14	12	14	0	0	0	0	10	10	10	10	36	39	67	69	42	47	49	54
252	1/31/2006	Concealed	53	F	0.7	0.8	0.9	1.0	0.2	0.2	0.4	0.29	0.25	0.44	158	70	15	15	15	35	14	15	16	16	0	0	0	0	10	10	10	10	39	40	41	61	47	47	64	80
253	2/4/2006	Concealed	52	F	0.5	0.4	0.8	0.8	0.3	0.4	0.7	0.60	1.00	0.88	159	80	0	0	10	10	14	15	16	14	0	0	0	0	10	10	10	10	24	25	36	34	46	46	64	64
254	2/1/2006	Concealed	55	F	0.7	0.7	0.9	0.8	0.2	0.1	0.3	0.29	0.14	0.33	160	78	0	0	0	0	14	15	16	16	0	0	5	5	10	10	10	10	24	25	31	31	17	17	42	42
255	2/1/2006	Concealed	70	F	0.5	0.5	0.7	0.7	0.2	0.2	0.4	0.40	0.40	0.57	148	76	15	15	0	0	14	14	15	16	0	0	0	0	10	10	8	10	39	39	23	26	23	23	23	23
256	2/2/2006	Concealed	68	F	0.6	0.5	0.8	0.9	0.2	0.4	0.6	0.33	0.80	0.75	149	55	15	15	15	15	14	15	16	16	0	0	0	0	10	10	10	10	39	40	41	41	23	23	36	36
257	2/2/2006	Concealed	71	F	0.4	0.4	0.8	0.9	0.4	0.5	0.9	1.00	1.25	1.13	144	54	0	0	10	10	16	15	16	16	0	0	0	0	5	10	10	10	21	25	36	36	23	23	23	26
268	2/18/2006	Concealed	55	F	0.7	0.7	1.1	1.0	0.4	0.3	0.7	0.57	0.43	0.64	160	82	10	10	10	10	14	14	15	15	5	10	10	10	10	10	10	10	39	44	45	45	72	72	74	74
275	2/24/2006	Concealed	74	F	0.5	0.4	0.9	0.9	0.4	0.5	0.9	0.80	1.25	1.00	153	66	0	0	10	10	14	14	15	14	0	0	0	0	10	10	10	10	24	24	35	34	27	32	34	32